Company BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for BenevolentAI

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 10:08:14 2024-05-24 am EDT			5-day change	1st Jan Change
0.576 ^EUR	-4.00%		+0.70%	-46.67%

May. 15	BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	CI
May. 02	Benevolentai S.A. Announces Directorate Changes	CI

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.

The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.

Number of employees: 248

Managers	Title	Age	Since
Ivan Griffin FOU	Founder	48	13-10-31
Catherine Isted DFI	Director of Finance/CFO	-	23-09-10
Constantinos Neophytou CTO	Chief Tech/Sci/R&D Officer	-	20-06-30
Anne Phelan CTO	Chief Tech/Sci/R&D Officer	59	19-10-31
Fleur Wood IRC	Investor Relations Contact	-	-
Anna Fullerton Batten HRO	Human Resources Officer	-	22-08-31
Christina Busmalis PRN	Corporate Officer/Principal	-	23-09-17
Catherine Tucker PRN	Corporate Officer/Principal	-	19-10-31
William Scrimshaw LAW	General Counsel	-	19-02-28

Members of the board	Title	Age	Since
Nigel Shadbolt BRD	Director/Board Member	68	20-06-30
Jean Raby BRD	Director/Board Member	60	22-04-21
John Orloff BRD	Director/Board Member	66	21-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	142,626,303	75,652,018 ( 53.04 %)	20,686,419 ( 14.50 %)	53.04 %

Name	Equities	%	Valuation
Kenneth Patrick Mulvany 23.78 %	33,912,333	23.78 %	23 M €
Michael Brennan 3.239 %	4,619,160	3.239 %	3 M €
Jean Raby 0.4570 %	651,745	0.4570 %	446 002 €
DNCA Finance SA 0.3196 %	455,832	0.3196 %	311 935 €
Olivier Brandicourt 0.3046 %	434,495	0.3046 %	297 334 €
Ann Hunter 0.1349 %	192,465	0.1349 %	131 708 €

Name	Equities	%	Valuation
Evelyn Partners Investment Management LLP 0.4000 %	40,000	0.4000 %	428 €
Decalia SA 0.3060 %	30,600	0.3060 %	327 €
Evelyn Partners Fund Solutions Ltd. 0.2000 %	20,000	0.2000 %	214 €

BenevolentAI SA

4-8 Maple Street

W1T 5HD, London

http://www.benevolent.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4905 GBP

Average target price

1.935 GBP

Spread / Average Target

+294.49%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-46.67%	76.24M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research